Drugs / DC/AML Fusion Vaccine
DC/AML Fusion Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03059485 | Jun 2017 → Sep 2026 expected | acute myeloid leukemia | Beth Israel Deaconess Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC/AML Fusion Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03059485 ↗ |
| Known as | DC/AML vaccine | “Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)” NCT03059485 ↗ |
| Known as | Dendritic Cell/AML Fusion vaccine | “Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)” NCT03059485 ↗ |
| Modality | Vaccine | “a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)” NCT03059485 ↗ |